Search Results
Your search for ,had matches 18486 pages
Showing 5401 - 5450Expert Point of View: Thomas Seufferlein, MD, PhD
The invited discussant of APACT,1 Thomas Seufferlein, MD, PhD, Professor of Medicine at the University of Ulm in Germany, said the updated overall survival data “suggest an improved outcome with nab-paclitaxel plus gemcitabine vs gemcitabine alone…. The combination improves long-term survival and...
APACT: 5-Year Overall Survival Data Suggest Improved Outcomes in Pancreatic Cancer With Nab-paclitaxel/Gemcitabine
The 5-year outcomes in the APACT trial uphold the overall survival benefit with nab-paclitaxel plus gemcitabine in the adjuvant treatment of patients with resected pancreatic cancer, according to Margaret A. Tempero, MD, Director of the University of California San Francisco Pancreas Center, who...
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer “next-generation ...
Disparities Observed in Follow-up Care Among Young Adult Childhood Cancer Survivors
A research team examined gaps and disparities in lifelong follow-up among childhood cancer survivors, including taking a closer look at long-term follow-up care plans, specifically for underserved populations. Their study showed that age and ethnic background are associated with inadequate...
Topical HDAC Inhibitor Remetinostat for Basal Cell Carcinoma
A small phase II study of the topical histone deacetylase (HDAC) inhibitor remetinostat in patients with basal cell carcinoma found that the therapy was well tolerated and demonstrated clinical efficacy with no systemic side effects. The findings suggest that HDAC inhibitors are likely an effective ...
S-1 Chemoradiation vs Radiotherapy Alone in Patients Aged 70 to 85 With Esophageal Cancer
In a Chinese phase III trial reported in JAMA Oncology, Ji et al found that concurrent chemoradiation with S-1 was associated with improved overall survival and acceptable toxicity vs radiotherapy alone in older patients with esophageal cancer. As stated by the investigators, “Most older patients ...
Pertuzumab and Trastuzumab in Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
As reported in The Lancet Oncology by Milind Javle, MD, and colleagues, findings in a cohort of the phase IIa MyPathway multiple basket study showed that the combination of pertuzumab and trastuzumab produced responses in some previously treated patients with HER2-positive metastatic biliary tract...
Study Finds COVID-19 Vaccine Is Safe in Patients With Hematologic Malignancies, but 25% of These Patients Do Not Produce Detectable Antibodies
About one in four patients with blood cancer fail to produce detectable antibodies after COVID-19 vaccination, but results vary substantially by type of blood cancer, according to a study by Greenberger et al published in the journal Cancer Cell. Although earlier studies have shown that certain...
Facing the Trauma of Colorectal Cancer
I first noticed blood in my stool when I was in the 8th grade. My mom and I did an Internet search and were relieved to find that the cause was most likely nothing more serious than hemorrhoids, so I put the problem out of my mind. I played volleyball and had an active social life, and the...
2021 ASCO Annual Meeting: Next-Generation Oncology Highlights
The 2021 ASCO Annual Meeting was presented totally virtually again due to the persistence of the COVID-19 pandemic. Nevertheless, the meeting held widespread interest, and we were able to attend an event with important changes for the practice of oncology. Compared with 2020, fewer...
Comparison of I-131 Metaiodobenzylguanidine–Containing Regimens in Relapsed or Refractory Neuroblastoma
In a phase II New Approaches to Neuroblastoma Therapy (NANT) consortium study reported in the Journal of Clinical Oncology, DuBois et al found that combining the radiotherapeutic I-131 metaiodobenzylguanidine (MIBG) with vorinostat produced a higher response rate in relapsed or refractory...
From Istanbul to Orange County, an Oncologist’s Journey to a Leadership Role in Quality Care
Pelin Cinar, MD, MS, was born and reared in Istanbul, Turkey. “My father ran a small furniture business, and my mother was a homemaker. However, I had a distant cousin who was an obstetrician-gynecologist, but he did house calls and treated any number of health issues in the community. Early on, I ...
CAR T-Cell Gene Therapy in Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel gene therapies for resistant non-Hodgkin lymphomas (NHL), including...
A New Era of Hope for Patients With Triple-Negative Breast Cancer
Triple-negative breast cancer is a particularly devastating subtype of breast cancer, as it is often diagnosed in young women and is associated with an exceptionally poor prognosis. The “triple-negative” designation indicates that the three key features driving most breast cancers (estrogen...
Is Disease-Free Survival the Best Endpoint for Adjuvant Nivolumab in High-Risk, Muscle-Invasive Urothelial Carcinoma?
The role of adjuvant treatment for invasive, high-grade bladder cancer remains controversial and challenging. Sternberg et al reported a statistically significant progression-free survival benefit from adjuvant combination gemcitabine/cisplatin (GC) or MVAC (methotrexate, vinblastine, doxorubicin, ...
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported inThe New England Journal of Medicine by Dean F. Bajorin, MD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo...
Adding Short-Term Androgen Suppression to Radiotherapy for Patients With Localized Intermediate-Risk Prostate Cancer: Long-Term Findings
As reported in the Journal of Clinical Oncology by Bolla et al, a 12-year analysis among patients with localized intermediate-risk prostate cancer in the EORTC 22991 trial showed improved event-free and disease-free survival with the addition of 6 months of concomitant and adjuvant androgen...
Outcomes With 2 vs 5 Years of Hormone Therapy Following Adjuvant Endocrine Therapy in Postmenopausal Women With HR-Positive Breast Cancer
In a phase III trial reported in The New England Journal of Medicine, Michael Gnant, MD, and colleagues found no difference in disease-free survival with 2 vs 5 years of treatment with the aromatase inhibitor anastrozole in postmenopausal women with early hormone receptor (HR)-positive breast...
Cutaneous HPV May Be a Predictor of Cutaneous Squamous Cell Carcinoma Risk
In an article published by Rollison et al in Cancer Research, researchers demonstrated a link between the presence of cutaneous human papillomavirus (HPV) and the incidence of cutaneous squamous cell carcinomas. They also identified key characteristics of infection that may contribute to...
An Egyptian Surgical Oncologist Urges Global Cooperation to Achieve Equitable Cancer Care
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ashraf Zaghloul, MD, DrPH, Professor at the National Cancer Institute of Egypt and President of the Egyptian Society of Surgical Oncology. Dr. Zaghloul was born in 1956 in ...
Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML
Aspacytarabine, a cytarabine prodrug, was reported to be safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who were unfit for intensive induction chemotherapy, according to the results of a phase II study presented during the 2021 ASCO Annual Meeting.1 The...
Use of Statins and Survival Outcomes Among Patients With Triple-Negative Breast Cancer
A study published by Nowakowska et al in the journal Cancer has found a significant association between the use of cholesterol-lowering statins and survival rates of patients with triple-negative breast cancer. Since statins are relatively inexpensive, easy to access, and produce minimal side...
Study Highlights Gaps in Mental Health and Chemical Dependency Care at U.S. Cancer Centers
Research published by Niazi et al in JNCCN—Journal of the National Comprehensive Cancer Network indicates a need to increase mental health and chemical dependency support capabilities at cancer centers across the United States. Previous studies have determined that people diagnosed with cancer...
Does Pain Affect the Employment and Financial Outcomes of Cancer Survivors?
In a study reported in the Journal of Clinical Oncology, Halpern et al found that cancer survivors with pain had worse employment and financial outcomes than did those reporting no pain. Study Details The study used data from 1,213 adult survivors identified from the 2016–2017 Medical Expenditure...
Revised Children’s Oncology Group Neuroblastoma Risk Classification System
As reported in the Journal of Clinical Oncology by Irwin et al, the Children’s Oncology Group (COG) has developed a new neuroblastoma risk classification (COG version 2) that uses the International Neuroblastoma Risk Group Staging System (INRGSS) and incorporates segmental chromosome aberrations as ...
Second-Generation Androgen Receptor Inhibitors for Older Men With Nonmetastatic Castration-Resistant Prostate Cancer
In a U.S. Food and Drug Administration pooled analysis of clinical trial patient-level data reported in The Lancet Oncology, Fallah et al found that second-generation androgen receptor inhibitor treatment was associated with survival benefits in patients aged 80 years or older with nonmetastatic...
Expert Point of View: Chris Verslype, MD, PhD
The invited discussant of the RATIONALE 208 trial, Chris Verslype, MD, PhD, Professor of Medicine at University Hospitals Leuven in Belgium, said tislelizumab is an “active and safe” investigational PD-1 antibody, “comparable to other PD-1 agents.” In particular, he noted, the results of RATIONALE ...
RATIONALE 208: ‘Durable Clinical Activity’ Reported With Tislelizumab in Advanced Liver Cancer
With the investigational checkpoint inhibitor tislelizumab, durable responses were achieved by some patients with previously treated advanced hepatocellular carcinoma, regardless of the number of prior lines of therapy, in the phase II RATIONALE 208 trial. These findings were presented during the...
Maintaining a Healthy Lifestyle May Decrease Cancer Incidence in High-Risk Individuals
Studies show that unhealthy lifestyles—including smoking, drinking alcohol, having obesity, being physically inactive, and eating a poor diet—are associated with an increased risk of developing cancer. Studies also show that practicing a healthy lifestyle is associated with an increase in total...
Racial/Ethnic Disparities in Emergency Department Visits After Breast Cancer Surgery
Among women undergoing surgery for breast cancer, up to 13% will have a postoperative visit to an emergency department, according to recent research. A new study published by Falcone et al in Breast Cancer Research and Treatment discovered there is a greater likelihood that Hispanic and...
Pulsed Vincristine/Dexamethasone Maintenance in Pediatric Acute Lymphoblastic Leukemia
In a Chinese phase III trial (CCCG-ALL-2015) reported in The Lancet Oncology, Yang et al found that 1 year of maintenance therapy with pulsed vincristine and dexamethasone was noninferior to 2 years in low-risk pediatric patients with acute lymphoblastic leukemia and was borderline inferior in...
Neoadjuvant Cabozantinib/Nivolumab May Make Resection Possible for Some Patients With Liver Cancer
A combination of the kinase inhibitor cabozantinib and the immunotherapy nivolumab may make curative surgery possible for some patients with liver cancer who would generally not be considered candidates for surgery, according to research published by Ho et al in Nature Cancer. Rates of Resection...
Breakthrough COVID-19 Infection in Fully Vaccinated Health-Care Workers
In an Israeli single-institution prospective cohort study reported in The New England Journal of Medicine, Bergwerk et al identified breakthrough COVID-19 infections among 39 of 1,497 health-care workers fully vaccinated with the BNT162b2 (Pfizer-BioNTech) vaccine. As stated by the investigators:...
Impact of Nurse Navigation Program on Outcomes in Minority Patients With Aggressive Lymphoma
In a single-institution study reported in the journal Cancer, Hu et al found that use of a dedicated nurse navigation program contributed to redressing the recognized inequities in care and outcomes between minority patients and White patients with aggressive large B-cell lymphoma (LBCL). As...
KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer
The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer.1 This is the first large, randomized, phase III...
Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
The session’s invited discussant Surbhi Sidana, MD, Assistant Professor of Medicine, Stanford University, said CAR T-cell therapy and bispecific antibodies targeting myeloma are emerging as potentially effective options for patients with highly refractory disease. For this population of triple...
Bispecific Antibodies Advance in Relapsed or Refractory Multiple Myeloma
For the challenging population of patients with multiple myeloma who have become refractory to essentially all current treatments, new approaches are much needed. Early clinical trials data suggest bispecific antibodies may help meet this need, as suggested by studies presented at the 2021 ASCO...
Study Shows Cancer Trials Adapted Rapidly During the COVID-19 Pandemic
Cancer clinical trial research rapidly adapted to the circumstances of enrolling and treating patients in clinical trials during the COVID-19 pandemic, according to findings from a study of enrollment during 2020 and early 2021 published by Joseph M. Unger, PhD, and colleagues in JAMA Network ...
Meta-analysis Identifies Genetic Markers for Inherited Testicular Cancer
A meta-analysis of nearly 200,000 men revealed 22 new genetic locations that could be susceptible to inherited testicular germ cell tumors—a 40% increase in the number of regions known to be associated with the cancer. The new findings, published by Pluta et al in Nature Communications, could help...
Incidence of Axillary Adenopathy in Screening or Diagnostic Mammography After COVID-19 Vaccination
In a single-center retrospective study reported in a research letter in JAMA Oncology, Robinson et al found a vaccine-related axillary adenopathy incidence rate of 3% among women undergoing screening or diagnostic mammography within 90 days of receipt of at least one dose of a COVID-19 vaccine....
Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors
In a prospective study from the St. Jude Lifetime Cohort reported in the Journal of Clinical Oncology, Williams et al found that prefrailty and frailty among young adult childhood cancer survivors were associated with neurocognitive decline vs nonfrail counterparts, mirroring the association...
Association of Baseline Fatigue With Survival and Adverse Events in Patients With Advanced Cancer
In an analysis of four SWOG clinical trials of patients with advanced cancer reported in JCO Oncology Practice, Mo et al found that clinically significant fatigue at baseline was associated with poorer survival and increased risk of severe adverse events. Study Details The analysis included data...
Perioperative or Postoperative Oxaliplatin/S-1 vs Postoperative Oxaliplatin/Capecitabine for Locally Advanced Gastric Cancer
In the Chinese phase III RESOLVE trial reported in The Lancet Oncology, Zhang et al found that perioperative S-1/oxaliplatin was superior to—and adjuvant S-1/oxaliplatin was noninferior to—adjuvant capecitabine/oxaliplatin in terms of disease-free survival in patients undergoing D2 gastrectomy for...
Single-Agent Talazoparib Shows Activity in the Neoadjuvant Treatment of Triple-Negative Breast Cancer
For the neoadjuvant treatment of triple-negative breast cancer, the oral poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib yielded promising pathologic complete response rates in the phase II single-arm NEOTALA trial presented at the 2021 ASCO Annual Meeting.1 Preoperative chemotherapy is...
How Climate Change Is Impacting Cancer Care and What Can Be Done to Reduce Oncology’s Footprint on the Environment
Worldwide, the global average surface temperature has risen at a similar rate of 0.17°F per decade since 1901, with the warmest year on record occurring in 2016 and the second warmest occurring in 2020. However, according to NOAA, since the late 1970s, the United States has warmed faster than the...
Complication Rates Among Central Venous Access Devices Compared
In the CAVA trial reported in The Lancet, Moss et al found that among central venous access devices used for the delivery of systemic anticancer therapy, totally implanted ports (PORTs) were associated with significantly reduced rates of complications compared with Hickman-type tunneled catheters...
Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in Nature Cancer. The research...
Expert Point of View: Evandro de Azambuja, MD, PhD
“KAITLIN didnot meet its primary endpoint, either in the intent-to-treat or node-positive population,1 but in context with the APHINITY trial [1 year of adjuvant pertuzumab/trastuzumab plus chemotherapy],2 whose outcomes were similar at 3 years, you can appreciate that both arms did extremely...
Cancer vs Non–Cancer-Related Deaths Among Older Patients Selected for Surgical Treatment
In a Canadian population-based cohort study reported in JAMA Surgery, Chesney et al found that the 5-year rate of cancer-related deaths exceeded that of non–cancer-related deaths among patients aged 70 or older undergoing surgery for cancer. Study Details The study used data from ICES (formerly...
